
Merck, Moderna's Personalized Cancer Vaccine Shows Promise in Late-Stage Trial
Merck and Moderna's mRNA-based personalized cancer vaccine, combined with Keytruda, showed positive results in a Phase 3 trial for advanced melanoma, significantly extending recurrence-free survival and reducing distant metastasis risk.



















